Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.

Nicholas C TurnerJudith BalmañaCoralie PoncetTheodora GouliotiKonstantinos TryfonidisAafke H HonkoopGabriele ZoppoliEvangelia D RazisOskar T JohannssonMarco Colleoni Andrew N J TuttWilliam AudehMichail IgnatiadisAudrey MailliezOlivier Trédan Antonino MusolinoPeter VuylstekeMaria Jose Juan-FitaIain R J MacphersonBella KaufmanLuis MansoLori J GoldsteinSusan L EllardIstván LángKai Yu Jen Virginie AdamSaskia LitièreJohn ErbanDavid A Cameronnull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Informative censoring in the control arm prevented accurate assessment of the trial hypothesis, although there was clear evidence of niraparib's activity in this patient population.

Keyphrases

breast cancer risk
study protocol
case report
high resolution
big data
randomized controlled trial
dna repair
phase iii
dna damage
mass spectrometry